CMG 017
Alternative Names: CMG-017Latest Information Update: 28 Jun 2023
Price :
$50 *
At a glance
- Originator CMG Pharmaceutical
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in South Korea (PO)
- 31 May 2019 Preclinical trials in Cancer in South Korea (PO) before May 2019
- 31 May 2019 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)